MedTrace Logo

Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma

NCT01186978 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2020-06-02

Study results available
· View outcomes & findings →

Summary

This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity.

Hypothesis- The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET scan following rituximab-containing chemotherapy.

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

RADIATION

Radiation Therapy

1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week

Sponsors & Collaborators

Principal Investigators

  • Christopher Kelsey, MD · Duke University Medical Center, Radiation Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-20
Primary Completion
2019-06-04
Completion
2019-06-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01186978 on ClinicalTrials.gov